



ASX ANNOUNCEMENT

11 January 2018

Release of Securities from Voluntary Escrow

Melbourne, Australia; 11 January 2018: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), advises in accordance with ASX Listing Rule 3.10A that the following securities will be released from voluntary escrow:

Security	Number	Release Date
Ordinary Shares	8,088,403	27 January 2018

Peter Webse
Company Secretary

CONTACTS: Dr Ross Macdonald, CEO: Tel: 0412 119343; email ross.macdonald@cynata.com
Daniel Paproth, Australia Media Contact, +61 (0)421 858 982 , daniel.paproth@mcpartners.com.au
Laura Bagby, U.S. Media Contact, 312-448-8098, lbagby@6degreespr.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical stage stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology addresses a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ utilises induced pluripotent stem cells (iPSCs) to produce a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ platform provides a source of MSCs that is independent of donor limitations and provides an “off-the-shelf” stem cell platform for therapeutic product use, with a pharmaceutical product business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.